{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T09:18:43Z","timestamp":1760347123582,"version":"3.37.3"},"reference-count":203,"publisher":"Bentham Science Publishers Ltd.","issue":"9","funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Government of India","doi-asserted-by":"publisher","award":["BT\/PR22952\/NER\/95\/572\/2017"],"award-info":[{"award-number":["BT\/PR22952\/NER\/95\/572\/2017"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2023,8,7]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>The prevalence of drug-resistant organisms has steadily increased over the past few decades worldwide. Especially in tuberculosis (TB) disease, the problems of co-morbidity and the rapid emergence of multidrug resistance have necessitated the development of multitarget-based therapeutic regimens. Several multitargeting compounds against Mycobacterium tuberculosis (Mtb) have been studied through novel in silico tools but these have rendered reduced efficacy in clinical trials. The authors have focussed on many exotic targets belonging to crucial Mtb survival pathways whose molecular structures and functions are underexplored. Likewise, insights into the hidden possibilities of promiscuous compounds from natural products or repurposed drugs to inhibit other cellular proteins apart from their validated targets are also depicted in this review. In addition to the existing line of drugs currently recommended for multidrug-resistant TB, newer host-directed therapies could also be fruitful. Furthermore, several challenges, including safety\/efficacy ratios of multitarget compounds highlighted here, can also be circumnavigated by researchers to design \u201csmart drugs\u201d for improved tuberculosis therapeutics.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>A holistic approach towards alleviating the existing drawbacks of drug discovery in drug-resistant TB has been outlined. Finally, considering the current needs, the authors have put forward an overall summary of possible trends in multitargeting that are significant for futuristic therapeutic solutions.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389450124666230505145335","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T05:32:06Z","timestamp":1683523926000},"page":"751-775","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Multitargeting: An Alternative Approach to Tackle Multidrug Resistance\nin Tuberculosis"],"prefix":"10.2174","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6255-5592","authenticated-orcid":true,"given":"Satakshi","family":"Hazra","sequence":"first","affiliation":[{"name":"Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati-781039, Assam, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8396-8433","authenticated-orcid":true,"given":"Risha","family":"Hazarika","sequence":"additional","affiliation":[{"name":"School of Agro and Rural Technology, Indian Institute of Technology Guwahati, Guwahati-781039, Assam, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8624-3323","authenticated-orcid":true,"given":"Sanjukta","family":"Patra","sequence":"additional","affiliation":[{"name":"Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati-781039, Assam, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"year":"2021","key":"ref=1","unstructured":"Global Tuberculosis Report. World Health Organization 2021"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"612675","DOI":"10.3389\/fmicb.2021.612675","volume":"12","author":"Allu\u00e9-Guardia A.","year":"2021","unstructured":"Allu\u00e9-Guardia A.; Garc\u00eda J.I.; Torrelles J.B.; Evolution of drug-resistant Mycobacterium tuberculosis strains and their adaptation to the human lung environment. Front Microbiol 2021,12,612675","journal-title":"Front Microbiol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3390\/pharmaceutics13050592","volume":"13","author":"Stephanie F.","year":"2021","unstructured":"Stephanie F.; Saragih M.; Tambunan U.S.F.; Recent progress and challenges for drug-resistant tuberculosis treatment. Pharmaceutics 2021,13(5),592","journal-title":"Pharmaceutics"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1021\/acsinfecdis.0c00001","volume":"6","author":"Gray D.A.","year":"2020","unstructured":"Gray D.A.; Wenzel M.; Multitarget approaches against multiresistant superbugs. ACS Infect Dis 2020,6(6),1346-1365","journal-title":"ACS Infect Dis"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1021\/jm500131s","volume":"57","author":"Li K.","year":"2014","unstructured":"Li K.; Schurig-Briccio L.A.; Feng X.; Multitarget drug discovery for tuberculosis and other infectious diseases. J Med Chem 2014,57(7),3126-3139","journal-title":"J Med Chem"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"a017863","DOI":"10.1101\/cshperspect.a017863","volume":"5","author":"Seung K.J.","year":"2015","unstructured":"Seung K.J.; Keshavjee S.; Rich M.L.; Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med 2015,5(9),a017863","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"6413","DOI":"10.1128\/AAC.03229-14","volume":"58","author":"Li W.","year":"2014","unstructured":"Li W.; Upadhyay A.; Fontes F.L.; Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014,58(11),6413-6423","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"10583","DOI":"10.1021\/acs.jmedchem.9b01716","volume":"62","author":"Harrison J.","year":"2019","unstructured":"Harrison J.; Cox J.A.G.; Changing the rules of TB-drug discovery. J Med Chem 2019,62(23),10583-10585","journal-title":"J Med Chem"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.2147\/DDDT.S257494","volume":"14","author":"Makhoba X.H.","year":"2020","unstructured":"Makhoba X.H.; Viegas C.; Mosa R.A.; Viegas F.P.D.; Pooe O.J.; Potential impact of the multi-target drug approach in the treatment of some complex diseases. Drug Des Devel Ther 2020,14,3235-3249","journal-title":"Drug Des Devel Ther"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40169-017-0181-2","volume":"7","author":"Ramsay R.R.","year":"2018","unstructured":"Ramsay R.R.; Popovic-Nikolic M.R.; Nikolic K.; Uliassi E.; Bolognesi M.L.; A perspective on multi\u2010target drug discovery and design for complex diseases. Clin Transl Med 2018,7(1),3","journal-title":"Clin Transl Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.ccm.2019.08.002","volume":"40","author":"Mase S.R.","year":"2019","unstructured":"Mase S.R.; Chorba T.; Treatment of drug-resistant tuberculosis. Clin Chest Med 2019,40(4),775-795","journal-title":"Clin Chest Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/cmdc.201600161","volume":"11","author":"Bolognesi M.L.","year":"2016","unstructured":"Bolognesi M.L.; Cavalli A.; Multitarget drug discovery and polypharmacology. ChemMedChem 2016,11(12),1190-1192","journal-title":"ChemMedChem"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1111\/jam.14478","volume":"128","author":"Singh R.","year":"2020","unstructured":"Singh R.; Dwivedi S.P.; Gaharwar U.S.; Meena R.; Rajamani P.; Prasad T.; Recent updates on drug resistance in Mycobacterium tuberculosis. J Appl Microbiol 2020,128(6),1547-1567","journal-title":"J Appl Microbiol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1021\/acsinfecdis.9b00112","volume":"5","author":"Lopez Quezada L.","year":"2019","unstructured":"Lopez Quezada L.; Li K.; McDonald S.L.; Dual-pharmacophore pyrithione-containing cephalosporins kill both replicating and nonreplicating Mycobacterium tuberculosis. ACS Infect Dis 2019,5(8),1433-1445","journal-title":"ACS Infect Dis"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"100285","DOI":"10.1016\/j.jctube.2021.100285","volume":"25","author":"Black T.A.","year":"2021","unstructured":"Black T.A.; Buchwald U.K.; The pipeline of new molecules and regimens against drug-resistant tuberculosis. J Clin Tuberc Other Mycobact Dis 2021,25,100285","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jgar.2021.02.017","volume":"25","author":"Khoshnood S.","year":"2021","unstructured":"Khoshnood S.; Goudarzi M.; Taki E.; Bedaquiline: Current status and future perspectives. J Glob Antimicrob Resist 2021,25,48-59","journal-title":"J Glob Antimicrob Resist"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.3389\/fmicb.2020.01924","volume":"11","author":"Boldrin F.","year":"2020","unstructured":"Boldrin F.; Provvedi R.; Cioetto Mazzab\u00f2 L.; Segafreddo G.; Manganelli R.; Tolerance and persistence to drugs: A main challenge in the fight against Mycobacterium tuberculosis. Front Microbiol 2020,11,1924","journal-title":"Front Microbiol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/antibiotics6010003","volume":"6","author":"Amaral L.","year":"2017","unstructured":"Amaral L.; Viveiros M.; Thioridazine: A non-antibiotic drug highly effective, in combination with first line anti-tuberculosis drugs, against any form of antibiotic resistance of Mycobacterium tuberculosis due to its multi-mechanisms of action. Antibiotics 2017,6(1),3","journal-title":"Antibiotics"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nrmicro1065","volume":"3","author":"Boshoff H.I.M.","year":"2005","unstructured":"Boshoff H.I.M.; Barry C.E.; Tuberculosis - metabolism and respiration in the absence of growth. Nat Rev Microbiol 2005,3(1),70-80","journal-title":"Nat Rev Microbiol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"5.1.16","DOI":"10.1128\/microbiolspec.TBTB2-0026-2016","volume":"5","author":"Hartman TE","year":"2017","unstructured":"Hartman TE; Wang Z; Jansen RS; Gardete S; Rhee KY; Metabolic perspectives on persistence. Microbiol Spectr 2017,5(1),5.1.16","journal-title":"Microbiol Spectr"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1021\/acsinfecdis.7b00231","volume":"4","author":"Lupoli T.J.","year":"2018","unstructured":"Lupoli T.J.; Vaubourgeix J.; Burns-Huang K.; Gold B.; Targeting the proteostasis network for mycobacterial drug discovery. ACS Infect Dis 2018,4(4),478-498","journal-title":"ACS Infect Dis"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1021\/acsinfecdis.8b00256","volume":"5","author":"Early J.","year":"2019","unstructured":"Early J.; Ollinger J.; Darby C.; Identification of compounds with ph-dependent bactericidal activity against Mycobacterium tuberculosis. ACS Infect Dis 2019,5(2),272-280","journal-title":"ACS Infect Dis"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1038\/s41467-021-24127-3","volume":"12","author":"Santucci P.","year":"2021","unstructured":"Santucci P.; Greenwood D.J.; Fearns A.; Chen K.; Jiang H.; Gutierrez M.G.; Intracellular localisation of Mycobacterium tuberculosis affects efficacy of the antibiotic pyrazinamide. Nat Commun 2021,12(1),3816","journal-title":"Nat Commun"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/j.biopha.2017.09.036","volume":"95","author":"Bhat Z.S.","year":"2017","unstructured":"Bhat Z.S.; Rather M.A.; Maqbool M.; Lah H.U.L.; Yousuf S.K.; Ahmad Z.; Cell wall: A versatile fountain of drug targets in Mycobacterium tuberculosis. Biomed Pharmacother 2017,95,1520-1534","journal-title":"Biomed Pharmacother"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.biopha.2018.04.176","volume":"103","author":"Bhat Z.S.","year":"2018","unstructured":"Bhat Z.S.; Rather M.A.; Maqbool M.; Ahmad Z.; Drug targets exploited in Mycobacterium tuberculosis: Pitfalls and promises on the horizon. Biomed Pharmacother 2018,103,1733-1747","journal-title":"Biomed Pharmacother"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1021\/acsinfecdis.7b00255","volume":"4","author":"Wellington S.","year":"2018","unstructured":"Wellington S.; Hung D.T.; The expanding diversity of mycobacterium tuberculosis drug targets. ACS Infect Dis 2018,4(5),696-714","journal-title":"ACS Infect Dis"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"126731","DOI":"10.1016\/j.bmcl.2019.126731","volume":"29","author":"Consalvi S.","year":"2019","unstructured":"Consalvi S.; Scarpecci C.; Biava M.; Poce G.; Mycobacterial tryptophan biosynthesis: A promising target for tuberculosis drug development? Bioorg Med Chem Lett 2019,29(23),126731","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.trsl.2020.03.007","volume":"220","author":"Shetye G.S.","year":"2020","unstructured":"Shetye G.S.; Franzblau S.G.; Cho S.; New tuberculosis drug targets, their inhibitors, and potential therapeutic impact. Transl Res 2020,220,68-97","journal-title":"Transl Res"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1039\/C5MD00376H","volume":"7","author":"Thanna S.","year":"2016","unstructured":"Thanna S.; Sucheck S.J.; Targeting the trehalose utilization pathways of Mycobacterium tuberculosis. Med Chem Comm 2016,7(1),69-85","journal-title":"Med Chem Comm"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/cbic.201800551","volume":"20","author":"Kapil S.","year":"2019","unstructured":"Kapil S.; Petit C.; Drago V.N.; Ronning D.R.; Sucheck S.J.; Synthesis and in vitro characterization of trehalose-based inhibitors of mycobacterial trehalose 6-phosphate phosphatases. Chem Bio Chem 2019,20(2),260-269","journal-title":"Chem Bio Chem"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ejmech.2017.02.001","volume":"128","author":"Liu C.","year":"2017","unstructured":"Liu C.; Dunaway-Mariano D.; Mariano P.S.; Rational design of reversible inhibitors for trehalose 6-phosphate phosphatases. Eur J Med Chem 2017,128,274-286","journal-title":"Eur J Med Chem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"e1006043","DOI":"10.1371\/journal.ppat.1006043","volume":"12","author":"Korte J.","year":"2016","unstructured":"Korte J.; Alber M.; Trujillo C.M.; Trehalose-6-phosphate-mediated toxicity determines essentiality of otsb2 in mycobacterium tuberculosisin vitro and in mice. PLoS Pathog 2016,12(12),e1006043","journal-title":"PLoS Pathog"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"14524","DOI":"10.1074\/jbc.M414232200","volume":"280","author":"Murphy H.N.","year":"2005","unstructured":"Murphy H.N.; Stewart G.R.; Mischenko V.V.; The OtsAB pathway is essential for trehalose biosynthesis in Mycobacterium tuberculosis. J Biol Chem 2005,280(15),14524-14529","journal-title":"J Biol Chem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"6091","DOI":"10.1046\/j.1432-1033.2002.03327.x","volume":"269","author":"Pan Y.T.","year":"2002","unstructured":"Pan Y.T.; Carroll J.D.; Elbein A.D.; Trehalose-phosphate synthase of Mycobacterium tuberculosis. Eur J Biochem 2002,269(24),6091-6100","journal-title":"Eur J Biochem"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"e02272","DOI":"10.1128\/mBio.02272-19","volume":"10","author":"Mendes V.","year":"2019","unstructured":"Mendes V.; Acebr\u00f3n-Garc\u00eda-de-Eulate M.; Verma N.; Blaszczyk M.; Dias M.V.B.; Blundell T.L.; Mycobacterial OtsA structures unveil substrate preference mechanism and allosteric regulation by 2-oxoglutarate and 2-phosphoglycerate. MBio 2019,10(6),e02272-e19","journal-title":"MBio"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"21761","DOI":"10.1073\/pnas.1014642108","volume":"107","author":"Kalscheuer R.","year":"2010","unstructured":"Kalscheuer R.; Weinrick B.; Veeraraghavan U.; Besra G.S.; Jacobs W.R.; Trehalose-recycling ABC transporter LpqY-SugA-SugB-SugC is essential for virulence of Mycobacterium tuberculosis. Proc Natl Acad Sci 2010,107(50),21761-21766","journal-title":"Proc Natl Acad Sci"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"9444","DOI":"10.1021\/jo501481r","volume":"79","author":"Veleti S.K.","year":"2014","unstructured":"Veleti S.K.; Lindenberger J.J.; Thanna S.; Ronning D.R.; Sucheck S.J.; Synthesis of a poly-hydroxypyrolidine-based inhibitor of Mycobacterium tuberculosis GlgE. J Org Chem 2014,79(20),9444-9450","journal-title":"J Org Chem"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1128\/AAC.45.5.1407-1416.2001","volume":"45","author":"Ma Y.","year":"2001","unstructured":"Ma Y.; Stern R.J.; Scherman M.S.; Drug targeting Mycobacterium tuberculosis cell wall synthesis: genetics of dTDP-rhamnose synthetic enzymes and development of a microtiter plate-based screen for inhibitors of conversion of dTDP-glucose to dTDP-rhamnose. Antimicrob Agents Chemother 2001,45(5),1407-1416","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1128\/JB.184.12.3392-3395.2002","volume":"184","author":"Ma Y.","year":"2002","unstructured":"Ma Y.; Pan F.; McNeil M.; Formation of dTDP-rhamnose is essential for growth of mycobacteria. J Bacteriol 2002,184(12),3392-3395","journal-title":"J Bacteriol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"7064","DOI":"10.1016\/j.bmcl.2011.09.094","volume":"21","author":"Wang Y.","year":"2011","unstructured":"Wang Y.; Hess T.N.; Jones V.; Zhou J.Z.; McNeil M.R.; Andrew McCammon J.; Novel inhibitors of Mycobacterium tuberculosis dTDP-6-deoxy-l-lyxo-4-hexulose reductase (RmlD) identified by virtual screening. Bioorg Med Chem Lett 2011,21(23),7064-7067","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.bmc.2009.11.033","volume":"18","author":"Sivendran S.","year":"2010","unstructured":"Sivendran S.; Jones V.; Sun D.; Identification of triazinoindol-benzimidazolones as nanomolar inhibitors of the Mycobacterium tuberculosis enzyme TDP-6-deoxy-d-xylo-4-hexopyranosid-4-ulose 3,5-epimerase (RmlC). Bioorg Med Chem 2010,18(2),896-908","journal-title":"Bioorg Med Chem"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1016\/S0960-894X(03)00673-5","volume":"13","author":"Babaoglu K.","year":"2003","unstructured":"Babaoglu K.; Page M.A.; Jones V.C.; Novel inhibitors of an emerging target in Mycobacterium tuberculosis; substituted thiazolidinones as inhibitors of dTDP-rhamnose synthesis. Bioorg Med Chem Lett 2003,13(19),3227-3230","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.compbiomed.2014.12.020","volume":"58","author":"Ren J.X.","year":"2015","unstructured":"Ren J.X.; Qian H.L.; Huang Y.X.; Zhu N.Y.; Si S.Y.; Xie Y.; Virtual screening for the identification of novel inhibitors of Mycobacterium tuberculosis cell wall synthesis: Inhibitors targeting RmlB and RmlC. Comput Biol Med 2015,58,110-117","journal-title":"Comput Biol Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2174\/1389201017666160909155959","volume":"17","author":"Mansuri R.","year":"2016","unstructured":"Mansuri R.; Ansari M.Y.; Singh J.; Computational elucidation of structural basis for ligand binding with mycobacterium tuberculosis glucose-1-phosphate thymidylyltransferase (RmlA). Curr Pharm Biotechnol 2016,17(12),1089-1099","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/9841250","volume":"2016","author":"Harathi N.","year":"2016","unstructured":"Harathi N.; Pulaganti M.; Anuradha C.M.; Kumar Chitta S.; Inhibition of Mycobacterium-RmlA by molecular modeling, dynamics simulation, and docking. Adv Bioinforma 2016,2016,1-13","journal-title":"Adv Bioinforma"},{"key":"ref=46","first-page":"B616","volume":"6","author":"Shefin B.","year":"2015","unstructured":"Shefin B.; Bindu A.; Virtual screening for identifying a putative inhibitor of rmlc a major target protein in tuberculosis disease. Int J Pharm Biol Sci 2015,6(4),B616-B628","journal-title":"Int J Pharm Biol Sci"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"43540","DOI":"10.1074\/jbc.M407782200","volume":"279","author":"Mills J.A.","year":"2004","unstructured":"Mills J.A.; Motichka K.; Jucker M.; Inactivation of the mycobacterial rhamnosyltransferase, which is needed for the formation of the arabinogalactan-peptidoglycan linker, leads to irreversible loss of viability. J Biol Chem 2004,279(42),43540-43546","journal-title":"J Biol Chem"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S1995-7645(11)60083-7","volume":"4","author":"Wu Q.","year":"2011","unstructured":"Wu Q.; Zhou P.; Qian S.; Cloning, expression, identification and bioinformatics analysis of Rv3265c gene from Mycobacterium tuberculosis in Escherichia coli. Asian Pac J Trop Med 2011,4(4),266-270","journal-title":"Asian Pac J Trop Med"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"e60143","DOI":"10.1371\/journal.pone.0060143","volume":"8","author":"Munshi T.","year":"2013","unstructured":"Munshi T.; Gupta A.; Evangelopoulos D.; Characterisation of ATP-dependent Mur ligases involved in the biogenesis of cell wall peptidoglycan in Mycobacterium tuberculosis. PLoS One 2013,8(3),e60143","journal-title":"PLoS One"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/2472555219881148","volume":"25","author":"Eniyan K.","year":"2020","unstructured":"Eniyan K.; Rani J.; Ramachandran S.; Bhat R.; Khan I.A.; Bajpai U.; Screening of antitubercular compound library identifies inhibitors of mur enzymes in Mycobacterium tuberculosis. SLAS Discov 2020,25(1),70-78","journal-title":"SLAS Discov"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3389\/fmicb.2019.00190","volume":"10","author":"Catal\u00e3o M.J.","year":"2019","unstructured":"Catal\u00e3o M.J.; Filipe S.R.; Pimentel M.; Revisiting anti-tuberculosis therapeutic strategies that target the peptidoglycan structure and synthesis. Front Microbiol 2019,10,190","journal-title":"Front Microbiol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s12539-012-0133-x","volume":"4","author":"Arvind A.","year":"2012","unstructured":"Arvind A.; Kumar V.; Saravanan P.; Mohan C.G.; Homology modeling, molecular dynamics and inhibitor binding study on MurD ligase of Mycobacterium tuberculosis. Interdiscip Sci 2012,4(3),223-238","journal-title":"Interdiscip Sci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"4997","DOI":"10.1080\/07391102.2019.1696231","volume":"38","author":"Kumar P.","year":"2020","unstructured":"Kumar P.; Saumya K.U.; Giri R.; Identification of peptidomimetic compounds as potential inhibitors against MurA enzyme of Mycobacterium tuberculosis. J Biomol Struct Dyn 2020,38(17),4997-5013","journal-title":"J Biomol Struct Dyn"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"697","DOI":"10.6026\/97320630010697","volume":"10","author":"Singh S.","year":"2014","unstructured":"Singh S.; Bajpai U.; Michael Lynn A.; Structure based virtual screening to identify inhibitors against MurE enzyme of Mycobacterium tuberculosis using AutoDock Vina. Bioinformation 2014,10(11),697-702","journal-title":"Bioinformation"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/jac\/dkv010","volume":"70","author":"Guzman J.D.","year":"2015","unstructured":"Guzman J.D.; Pesnot T.; Barrera D.A.; Tetrahydroisoquinolines affect the whole-cell phenotype of Mycobacterium tuberculosis by inhibiting the ATP-dependent MurE ligase. J Antimicrob Chemother 2015,70(6),1691-1703","journal-title":"J Antimicrob Chemother"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"8020","DOI":"10.1128\/JB.187.23.8020-8025.2005","volume":"187","author":"Miku\u0161ov\u00e1 K.","year":"2005","unstructured":"Miku\u0161ov\u00e1 K.; Huang H.; Yagi T.; Decaprenylphosphoryl arabinofuranose, the donor of the D-arabinofuranosyl residues of mycobacterial arabinan, is formed via a two-step epimerization of decaprenylphosphoryl ribose. J Bacteriol 2005,187(23),8020-8025","journal-title":"J Bacteriol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.2174\/092986710791959693","volume":"17","author":"Manina G.","year":"2010","unstructured":"Manina G.; Pasca M.R.; Buroni S.; De Rossi E.; Riccardi G.; Decaprenylphosphoryl-\u03b2-D-ribose 2\u2032-epimerase from Mycobacterium tuberculosis is a magic drug target. Curr Med Chem 2010,17(27),3099-3108","journal-title":"Curr Med Chem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"e0119771","DOI":"10.1371\/journal.pone.0119771","volume":"10","author":"Bhutani I.","year":"2015","unstructured":"Bhutani I.; Loharch S.; Gupta P.; Madathil R.; Parkesh R.; Structure, dynamics, and interaction of Mycobacterium tuberculosis (Mtb) DprE1 and DprE2 examined by molecular modeling, simulation, and electrostatic studies. PLoS One 2015,10(3),e0119771","journal-title":"PLoS One"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"e00681","DOI":"10.1128\/AAC.00681-18","volume":"62","author":"Piton J.","year":"2018","unstructured":"Piton J.; Vocat A.; Lupien A.; Structure-based drug design and characterization of sulfonyl-piperazine benzothiazinone inhibitors of dpre1 from Mycobacterium tuberculosis. Antimicrob Agents Chemother 2018,62(10),e00681-e18","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.drudis.2016.09.014","volume":"22","author":"Piton J.","year":"2017","unstructured":"Piton J.; Foo C.S.Y.; Cole S.T.; Structural studies of Mycobacterium tuberculosis DprE1 interacting with its inhibitors. Drug Discov Today 2017,22(3),526-533","journal-title":"Drug Discov Today"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13065-018-0441-2","volume":"12","author":"Gawad J.","year":"2018","unstructured":"Gawad J.; Bonde C.; Decaprenyl-phosphoryl-ribose 2\u2032-epimerase (DprE1): challenging target for antitubercular drug discovery. Chem Cent J 2018,12(1),72","journal-title":"Chem Cent J"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s12275-015-5333-8","volume":"53","author":"Korch S.B.","year":"2015","unstructured":"Korch S.B.; Malhotra V.; Contreras H.; Clark-Curtiss J.E.; The Mycobacterium tuberculosis relBE toxin:antitoxin genes are stress-responsive modules that regulate growth through translation inhibition. J Microbiol 2015,53(11),783-795","journal-title":"J Microbiol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/1574-6968.12074","volume":"340","author":"Schuster C.F.","year":"2013","unstructured":"Schuster C.F.; Bertram R.; Toxin-antitoxin systems are ubiquitous and versatile modulators of prokaryotic cell fate. FEMS Microbiol Lett 2013,340(2),73-85","journal-title":"FEMS Microbiol Lett"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3390\/toxins6031002","volume":"6","author":"Sala A.","year":"2014","unstructured":"Sala A.; Bordes P.; Genevaux P.; Multiple toxin-antitoxin systems in Mycobacterium tuberculosis. Toxins (Basel) 2014,6(3),1002-1020","journal-title":"Toxins (Basel)"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"e00100","DOI":"10.1128\/mBio.00100-11","volume":"2","author":"Keren I.","year":"2011","unstructured":"Keren I.; Minami S.; Rubin E.; Lewis K.; Characterization and transcriptome analysis of Mycobacterium tuberculosis persisters. MBio 2011,2(3),e00100-e00111","journal-title":"MBio"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"fty039","DOI":"10.1093\/femspd\/fty039","volume":"76","author":"Slayden R.A.","year":"2018","unstructured":"Slayden R.A.; Dawson C.C.; Cummings J.E.; Toxin\u2013antitoxin systems and regulatory mechanisms in Mycobacterium tuberculosis. Pathog Dis 2018,76(4),fty039","journal-title":"Pathog Dis"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s10989-018-9792-8","volume":"25","author":"Sundar S.","year":"2019","unstructured":"Sundar S.; Rajan M.P.; Piramanayagam S.; In silico derived peptides for inhibiting the toxin\u2013antitoxin systems of mycobacterium tuberculosis: Basis for developing peptide-based therapeutics. Int J Pept Res Ther 2019,25(4),1467-1475","journal-title":"Int J Pept Res Ther"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"e02133","DOI":"10.1128\/mBio.02133-16","volume":"8","author":"DeJesus M.A.","year":"2017","unstructured":"DeJesus M.A.; Gerrick E.R.; Xu W.; Comprehensive essentiality analysis of the Mycobacterium tuberculosis genome via saturating transposon mutagenesis. MBio 2017,8(1),e02133-e16","journal-title":"MBio"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.molcel.2019.01.028","volume":"73","author":"Freire D.M.","year":"2019","unstructured":"Freire D.M.; Gutierrez C.; Garza-Garcia A.; An NAD+ phosphorylase toxin triggers mycobacterium tuberculosis cell death. Mol Cell 2019,73(6),1282-1291.e8","journal-title":"Mol Cell"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3390\/ijms20020340","volume":"20","author":"Zhai W.","year":"2019","unstructured":"Zhai W.; Wu F.; Zhang Y.; Fu Y.; Liu Z.; The immune escape mechanisms of Mycobacterium tuberculosis. Int J Mol Sci 2019,20(2),340","journal-title":"Int J Mol Sci"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1046\/j.1365-2958.2003.03416.x","volume":"47","author":"Buchmeier N.A.","year":"2003","unstructured":"Buchmeier N.A.; Newton G.L.; Koledin T.; Fahey R.C.; Association of mycothiol with protection of Mycobacterium tuberculosis from toxic oxidants and antibiotics. Mol Microbiol 2003,47(6),1723-1732","journal-title":"Mol Microbiol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/B978-0-12-398264-3.00004-8","volume":"60","author":"Trivedi A.","year":"2012","unstructured":"Trivedi A.; Singh N.; Bhat S.A.; Gupta P.; Kumar A.; Redox biology of tuberculosis pathogenesis. Adv Microb Physiol 2012,60,263-324","journal-title":"Adv Microb Physiol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.cbpa.2009.07.018","volume":"13","author":"Fan F.","year":"2009","unstructured":"Fan F.; Vetting M.W.; Frantom P.A.; Blanchard J.S.; Structures and mechanisms of the mycothiol biosynthetic enzymes. Curr Opin Chem Biol 2009,13(4),451-459","journal-title":"Curr Opin Chem Biol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1177\/1087057109335743","volume":"14","author":"Gutierrez-Lugo M.T.","year":"2009","unstructured":"Gutierrez-Lugo M.T.; Baker H.; Shiloach J.; Boshoff H.; Bewley C.A.; Dequalinium, a new inhibitor of Mycobacterium tuberculosis mycothiol ligase identified by high-throughput screening. SLAS Discov 2009,14(6),643-652","journal-title":"SLAS Discov"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1517\/17460441.3.5.565","volume":"3","author":"Kapnick S.M.","year":"2008","unstructured":"Kapnick S.M.; Zhang Y.; New tuberculosis drug development: Targeting the shikimate pathway. Expert Opin Drug Discov 2008,3(5),565-577","journal-title":"Expert Opin Drug Discov"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3390\/molecules25061259","volume":"25","author":"Nunes J.E.S.","year":"2020","unstructured":"Nunes J.E.S.; Duque M.A.; de Freitas T.F.; Mycobacterium tuberculosis shikimate pathway enzymes as targets for the rational design of anti-tuberculosis drugs. Molecules 2020,25(6),1259","journal-title":"Molecules"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ejmech.2015.10.014","volume":"105","author":"Nirmal C.R.","year":"2015","unstructured":"Nirmal C.R.; Rao R.; Hopper W.; Inhibition of 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase from Mycobacterium tuberculosis: In silico screening and in vitro validation. Eur J Med Chem 2015,105,182-193","journal-title":"Eur J Med Chem"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/07391102.2019.1604468","volume":"37","author":"Madhulitha N.R.","year":"2019","unstructured":"Madhulitha N.R.; Kumar K.S.; Pasala C.; Pakala S.; Umamaheswari A.; Identification of potential inhibitors for AroG against Mycobacterium tuberculosis. J Biomol Struct Dyn 2019,37,29-30","journal-title":"J Biomol Struct Dyn"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"16197","DOI":"10.1074\/jbc.M110.211649","volume":"286","author":"Reichau S.","year":"2011","unstructured":"Reichau S.; Jiao W.; Walker S.R.; Hutton R.D.; Baker E.N.; Parker E.J.; Potent inhibitors of a shikimate pathway enzyme from Mycobacterium tuberculosis: Combining mechanism- and modeling-based design. J Biol Chem 2011,286(18),16197-16207","journal-title":"J Biol Chem"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"17439","DOI":"10.1038\/s41598-018-35701-z","volume":"8","author":"Zhu N.","year":"2018","unstructured":"Zhu N.; Wang X.; Li D.; IMB-T130 targets 3-dehydroquinate synthase and inhibits Mycobacterium tuberculosis. Sci Rep 2018,8(1),17439","journal-title":"Sci Rep"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"438","DOI":"10.36468\/pharmaceutical-sciences.528","volume":"81","author":"Sivaranjani P.","year":"2019","unstructured":"Sivaranjani P.; Naik V.U.; Madhulitha N.R.; Design of novel antimycobacterial molecule targeting shikimate pathway of Mycobacterium tuberculosis. Indian J Pharm Sci 2019,81(3),438-447","journal-title":"Indian J Pharm Sci"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s00894-018-3637-4","volume":"24","author":"Isa M.A.","year":"2018","unstructured":"Isa M.A.; Majumdhar R.S.; Haider S.; In silico docking and molecular dynamics simulation of 3-dehydroquinate synthase (DHQS) from Mycobacterium tuberculosis. J Mol Model 2018,24(6),132","journal-title":"J Mol Model"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.1021\/jm2006063","volume":"54","author":"Tiz\u00f3n L.","year":"2011","unstructured":"Tiz\u00f3n L.; Otero J.M.; Prazeres V.F.V.; A prodrug approach for improving antituberculosis activity of potent Mycobacterium tuberculosis type II dehydroquinase inhibitors. J Med Chem 2011,54(17),6063-6084","journal-title":"J Med Chem"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jmgm.2015.05.001","volume":"60","author":"Petersen G.O.","year":"2015","unstructured":"Petersen G.O.; Saxena S.; Renuka J.; Structure-based virtual screening as a tool for the identification of novel inhibitors against Mycobacterium tuberculosis 3-dehydroquinate dehydratase. J Mol Graph Model 2015,60,124-131","journal-title":"J Mol Graph Model"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.bbrc.2017.08.020","volume":"491","author":"Lone M.Y.","year":"2017","unstructured":"Lone M.Y.; Athar M.; Gupta V.K.; Jha P.C.; Prioritization of natural compounds against Mycobacterium tuberculosis 3-dehydroquinate dehydratase: A combined in-silico and in-vitro study. Biochem Biophys Res Commun 2017,491(4),1105-1111","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1042\/BJ20110002","volume":"436","author":"Dias M.V.B.","year":"2011","unstructured":"Dias M.V.B.; Snee W.C.; Bromfield K.M.; Structural investigation of inhibitor designs targeting 3-dehydroquinate dehydratase from the shikimate pathway of Mycobacterium tuberculosis. Biochem J 2011,436(3),729-739","journal-title":"Biochem J"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11030-019-10020-1","volume":"25","author":"Miranda P.H.S.","year":"2021","unstructured":"Miranda P.H.S.; Louren\u00e7o E.M.G.; Morais A.M.S.; Molecular modeling of a series of dehydroquinate dehydratase type II inhibitors of Mycobacterium tuberculosis and design of new binders. Mol Divers 2021,25(1),1-12","journal-title":"Mol Divers"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2174\/1568026613666131113150257","volume":"14","author":"Yao Y.","year":"2013","unstructured":"Yao Y.; Ze-Sheng L.; Structure-and-mechanism-based design and discovery of type II Mycobacterium tuberculosis dehydroquinate dehydratase inhibitors. Curr Top Med Chem 2013,14(1),51-63","journal-title":"Curr Top Med Chem"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2022.2042389","author":"Souza J.V.P.","year":"2022","unstructured":"Souza J.V.P.; Kioshima E.S.; Murase L.S.; Identification of new putative inhibitors of Mycobacterium tuberculosis 3-dehydroshikimate dehydratase from a combination of ligand- and structure-based and deep learning in silico approaches. J Biomol Struct Dyn 2022,1-10","journal-title":"J Biomol Struct Dyn"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.tube.2018.07.006","volume":"112","author":"Deng Q.","year":"2018","unstructured":"Deng Q.; Meng J.; Liu Y.; Guan Y.; Xiao C.; IMB-SD62, a triazolothiadiazoles derivative with promising action against tuberculosis. Tuberculosis 2018,112,37-44","journal-title":"Tuberculosis"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"PMC.S13212","DOI":"10.4137\/PMC.S13212","volume":"7","author":"Gordon S","year":"2015","unstructured":"Gordon S; Simithy J; Goodwin DC; Calder\u00f3n AI; Selective Mycobacterium tuberculosis shikimate kinase inhibitors as potential antibacterials. Perspect Medicin Chem 2015,7,PMC.S13212","journal-title":"Perspect Medicin Chem"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1021\/acs.jcim.6b00056","volume":"56","author":"Mehra R.","year":"2016","unstructured":"Mehra R.; Rajput V.S.; Gupta M.; Benzothiazole derivative as a novel Mycobacterium tuberculosis shikimate kinase inhibitor: Identification and elucidation of its allosteric mode of inhibition. J Chem Inf Model 2016,56(5),930-940","journal-title":"J Chem Inf Model"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.1007\/s00253-015-7268-8","volume":"100","author":"Rajput V.S.","year":"2016","unstructured":"Rajput V.S.; Mehra R.; Kumar S.; Nargotra A.; Singh P.P.; Khan I.A.; Screening of antitubercular compound library identifies novel shikimate kinase inhibitors of Mycobacterium tuberculosis. Appl Microbiol Biotechnol 2016,100(12),5415-5426","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref=94","first-page":"320","volume":"3","author":"Sahu P.K.","year":"2016","unstructured":"Sahu P.K.; Raval M.K.; Virtual screening for inhibitors of shikimate kinase of Mycobacterium tuberculosis. Pharm Biol Eval 2016,3,320-326","journal-title":"Pharm Biol Eval"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"4923","DOI":"10.1021\/acs.biochem.8b00231","volume":"57","author":"Simithy J.","year":"2018","unstructured":"Simithy J.; Fuanta N.R.; Alturki M.; Slow-binding inhibition of mycobacterium tuberculosis shikimate kinase by manzamine alkaloids. Biochemistry 2018,57(32),4923-4933","journal-title":"Biochemistry"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.bmcl.2017.12.002","volume":"28","author":"Alturki M.S.","year":"2018","unstructured":"Alturki M.S.; Fuanta N.R.; Jarrard M.A.; A multifaceted approach to identify non-specific enzyme inhibition: Application to Mycobacterium tuberculosis shikimate kinase. Bioorg Med Chem Lett 2018,28(4),802-808","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1099\/00221287-148-10-3069","volume":"148","author":"Parish T.","year":"2002","unstructured":"Parish T.; Stoker N.G.; The common aromatic amino acid biosynthesis pathway is essential in Mycobacterium tuberculosis. Microbiology (Reading) 2002,148(10),3069-3077","journal-title":"Microbiology (Reading)"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S0969-2126(03)00106-0","volume":"11","author":"Chaudhuri B.N.","year":"2003","unstructured":"Chaudhuri B.N.; Sawaya M.R.; Kim C.Y.; The crystal structure of the first enzyme in the pantothenate biosynthetic pathway, ketopantoate hydroxymethyltransferase, from M. tuberculosis. Structure 2003,11(7),753-764","journal-title":"Structure"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3389\/fphar.2015.00205","volume":"6","author":"Talevi A.","year":"2015","unstructured":"Talevi A.; Multi-target pharmacology: Possibilities and limitations of the \u201cskeleton key approach\u201d from a medicinal chemist perspective. Front Pharmacol 2015,6,205","journal-title":"Front Pharmacol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3390\/md16080279","volume":"16","author":"Lage O.M.","year":"2018","unstructured":"Lage O.M.; Ramos M.C.; Calisto R.; Almeida E.; Vasconcelos V.; Vicente F.; Current screening methodologies in drug discovery for selected human diseases. Mar Drugs 2018,16(8),279","journal-title":"Mar Drugs"},{"key":"ref=101","doi-asserted-by":"publisher","DOI":"10.5772\/65387","author":"Horman S.R.","year":"2016","unstructured":"Horman S.R.; Complex high-content phenotypic screening. Special Topics in Drug Discovery 2016","journal-title":"Special Topics in Drug Discovery"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.csbj.2016.04.004","volume":"14","author":"Katsila T.","year":"2016","unstructured":"Katsila T.; Spyroulias G.A.; Patrinos G.P.; Matsoukas M.T.; Computational approaches in target identification and drug discovery. Comput Struct Biotechnol J 2016,14,177-184","journal-title":"Comput Struct Biotechnol J"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1517\/17460441.2.6.799","volume":"2","author":"Korcsm\u00e1ros T.","year":"2007","unstructured":"Korcsm\u00e1ros T.; Szalay M.S.; B\u00f6de C.; Kov\u00e1cs I.A.; Csermely P.; How to design multi-target drugs. Expert Opin Drug Discov 2007,2(6),799-808","journal-title":"Expert Opin Drug Discov"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12859-019-2638-3","volume":"20","author":"Bang S.","year":"2019","unstructured":"Bang S.; Son S.; Kim S.; Shin H.; Disease pathway cut for multi-target drugs. BMC Bioinformatics 2019,20(1),74","journal-title":"BMC Bioinformatics"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1021\/acs.jcim.6b00491","volume":"57","author":"Zhang W.","year":"2017","unstructured":"Zhang W.; Pei J.; Lai L.; Computational multitarget drug design. J Chem Inf Model 2017,57(3),403-412","journal-title":"J Chem Inf Model"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41429-019-0205-9","volume":"72","author":"Grzelak E.M.","year":"2019","unstructured":"Grzelak E.M.; Choules M.P.; Gao W.; Strategies in anti-Mycobacterium tuberculosis drug discovery based on phenotypic screening. J Antibiot 2019,72(10),719-728","journal-title":"J Antibiot"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"e0205479","DOI":"10.1371\/journal.pone.0205479","volume":"14","author":"Ollinger J.","year":"2019","unstructured":"Ollinger J.; Kumar A.; Roberts D.M.; Bailey M.A.; Casey A.; Parish T.; A high-throughput whole cell screen to identify inhibitors of Mycobacterium tuberculosis. PLoS One 2019,14(1),e0205479","journal-title":"PLoS One"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bbapap.2018.08.002","volume":"1867","author":"Kubota K.","year":"2019","unstructured":"Kubota K.; Funabashi M.; Ogura Y.; Target deconvolution from phenotype-based drug discovery by using chemical proteomics approaches. Biochim Biophys Acta Proteins Proteomics 2019,1867(1),22-27","journal-title":"Biochim Biophys Acta Proteins Proteomics"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"11970","DOI":"10.1038\/srep11970","volume":"5","author":"Zheng C.","year":"2015","unstructured":"Zheng C.; Guo Z.; Huang C.; Large-scale direct targeting for drug repositioning and discovery. Sci Rep 2015,5(1),11970","journal-title":"Sci Rep"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.2174\/156802611795429185","volume":"11","author":"Wyatt P.G.","year":"2011","unstructured":"Wyatt P.G.; Gilbert I.H.; Read K.D.; Fairlamb A.H.; Target validation: Linking target and chemical properties to desired product profile. Curr Top Med Chem 2011,11(10),1275-1283","journal-title":"Curr Top Med Chem"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1038\/s41598-018-21614-4","volume":"8","author":"Chiarelli L.R.","year":"2018","unstructured":"Chiarelli L.R.; Mori G.; Orena B.S.; A multitarget approach to drug discovery inhibiting Mycobacterium tuberculosis PyrG and PanK. Sci Rep 2018,8(1),3187","journal-title":"Sci Rep"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3389\/fphar.2017.00539","volume":"8","author":"Deng Y.H.","year":"2017","unstructured":"Deng Y.H.; Wang N.N.; Zou Z.X.; Multi-target screening and experimental validation of natural products from Selaginella plants against Alzheimer\u2019s disease. Front Pharmacol 2017,8,539","journal-title":"Front Pharmacol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"16209","DOI":"10.1038\/s41598-019-52774-6","volume":"9","author":"Raj S.","year":"2019","unstructured":"Raj S.; Saha G.; Sasidharan S.; Dubey V.K.; Saudagar P.; Biochemical characterization and chemical validation of Leishmania MAP Kinase-3 as a potential drug target. Sci Rep 2019,9,16209","journal-title":"Sci Rep"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41598-018-37176-4","volume":"9","author":"T\u00fckenmez H.","year":"2019","unstructured":"T\u00fckenmez H.; Edstr\u00f6m I.; Ummanni R.; Mycobacterium tuberculosis virulence inhibitors discovered by Mycobacterium marinum high-throughput screening. Sci Rep 2019,9(1),26","journal-title":"Sci Rep"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1016\/j.csbj.2021.06.034","volume":"19","author":"Kingdon A.D.H.","year":"2021","unstructured":"Kingdon A.D.H.; Alderwick L.J.; Structure-based in silico approaches for drug discovery against Mycobacterium tuberculosis. Comput Struct Biotechnol J 2021,19,3708-3719","journal-title":"Comput Struct Biotechnol J"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/978-1-4939-6634-9_5","volume":"1520","author":"Yu W.","year":"2017","unstructured":"Yu W.; MacKerell A.D.; Computer-aided drug design methods. Antibiotics 2017,1520,85-106","journal-title":"Antibiotics"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3389\/fchem.2020.00176","volume":"8","author":"S\u00e1nchez-Tejeda J.F.","year":"2020","unstructured":"S\u00e1nchez-Tejeda J.F.; S\u00e1nchez-Ruiz J.F.; Salazar J.R.; Loza-Mej\u00eda M.A.; A definition of \u201cMultitargeticity\u201d: Identifying potential multitarget and selective ligands through a vector analysis. Front Chem 2020,8,176","journal-title":"Front Chem"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"e01010","DOI":"10.1590\/s2175-97902018000001010","volume":"54","author":"Viana JO","year":"2018","unstructured":"Viana JO; F\u00e9lix MB; Maia MS; Serafim VL; Scotti L; Scotti MT; Drug discovery and computational strategies in the multitarget drugs era. Braz J Pharm Sci 2018,54(spe),e01010","journal-title":"Braz J Pharm Sci"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.3390\/molecules25051239","volume":"25","author":"Stelitano G.","year":"2020","unstructured":"Stelitano G.; Sammartino J.C.; Chiarelli L.R.; Multitargeting compounds: A promising strategy to overcome multi-drug resistant tuberculosis. Molecules 2020,25(5),1239","journal-title":"Molecules"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.3390\/app10072339","volume":"10","author":"Foo C.S.Y.","year":"2020","unstructured":"Foo C.S.Y.; Pethe K.; Lupien A.; Oxidative phosphorylation-an update on a new, essential target space for drug discovery in Mycobacterium tuberculosis. Appl Sci 2020,10(7),2339","journal-title":"Appl Sci"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"E7073","DOI":"10.1073\/pnas.1521988112","volume":"112","author":"Feng X.","year":"2015","unstructured":"Feng X.; Zhu W.; Schurig-Briccio L.A.; Antiinfectives targeting enzymes and the proton motive force. Proc Natl Acad Sci 2015,112(51),E7073-E7082","journal-title":"Proc Natl Acad Sci"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1038\/s41467-020-15516-1","volume":"11","author":"Gopal P.","year":"2020","unstructured":"Gopal P.; Sarathy J.P.; Yee M.; Pyrazinamide triggers degradation of its target aspartate decarboxylase. Nat Commun 2020,11(1),1661","journal-title":"Nat Commun"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.biopha.2018.06.023","volume":"105","author":"Mirnejad R.","year":"2018","unstructured":"Mirnejad R.; Asadi A.; Khoshnood S.; Clofazimine: A useful antibiotic for drug-resistant tuberculosis. Biomed Pharmacother 2018,105,1353-1359","journal-title":"Biomed Pharmacother"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"215","DOI":"10.4161\/cib.2.3.7926","volume":"2","author":"Manjunatha U.","year":"2009","unstructured":"Manjunatha U.; Boshoff H.I.M.; Barry C.E.; The mechanism of action of PA-824. Commun Integr Biol 2009,2(3),215-218","journal-title":"Commun Integr Biol"},{"key":"ref=125","first-page":"74","volume":"7","author":"Bushra E.","year":"2016","unstructured":"Bushra E.; Adem J.; Mycobacterial metabolic pathways as drug targets: A review. Int J Microbiol Res 2016,7(3),74-87","journal-title":"Int J Microbiol Res"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/07391102.2012.691343","volume":"31","author":"Gahoi S.","year":"2013","unstructured":"Gahoi S.; Mandal R.S.; Ivanisenko N.; Computational screening for new inhibitors of M. tuberculosis mycolyltransferases antigen 85 group of proteins as potential drug targets. J Biomol Struct Dyn 2013,31(1),30-43","journal-title":"J Biomol Struct Dyn"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1080\/07391102.2020.1844055","volume":"40","author":"Ejalonibu M.A.","year":"2022","unstructured":"Ejalonibu M.A.; Elrashedy A.A.; Lawal M.M.; Kumalo H.M.; Mhlongo N.N.; Probing the dual inhibitory mechanisms of novel thiophenecarboxamide derivatives against Mycobacterium tuberculosis PyrG and PanK: An insight from biomolecular modeling study. J Biomol Struct Dyn 2022,40(7),2978-2990","journal-title":"J Biomol Struct Dyn"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/cbdd.13624","volume":"95","author":"Agre N.","year":"2020","unstructured":"Agre N.; Khambete M.; Maitra A.; Exploration of 5\u2010(5\u2010nitrothiophen\u20102\u2010yl)\u20104,5\u2010dihydro\u20101H\u2010pyrazoles as selective, multitargeted antimycobacterial agents. Chem Biol Drug Des 2020,95(1),192-199","journal-title":"Chem Biol Drug Des"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ejmech.2015.06.007","volume":"100","author":"Banerjee D.R.","year":"2015","unstructured":"Banerjee D.R.; Biswas R.; Das A.K.; Basak A.; Design, synthesis and characterization of dual inhibitors against new targets FabG4 and HtdX of Mycobacterium tuberculosis. Eur J Med Chem 2015,100,223-234","journal-title":"Eur J Med Chem"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.bioorg.2018.08.025","volume":"81","author":"Nguyen P.C.","year":"2018","unstructured":"Nguyen P.C.; Delorme V.; B\u00e9narouche A.; Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis. Bioorg Chem 2018,81,414-424","journal-title":"Bioorg Chem"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1021\/acs.biochem.5b00993","volume":"55","author":"Cheng Y.S.","year":"2016","unstructured":"Cheng Y.S.; Sacchettini J.C.; Structural Insights into Mycobacterium tuberculosis Rv2671 protein as a dihydrofolate reductase functional analogue contributing to para -aminosalicylic acid resistance. Biochemistry 2016,55(7),1107-1119","journal-title":"Biochemistry"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.chembiol.2019.02.013","volume":"26","author":"Hajian B.","year":"2019","unstructured":"Hajian B.; Scocchera E.; Shoen C.; Drugging the folate pathway in mycobacterium tuberculosis: The role of multi-targeting agents. Cell Chem Biol 2019,26(6),781-791.e6","journal-title":"Cell Chem Biol"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"23447","DOI":"10.1074\/jbc.M113.475798","volume":"288","author":"Zheng J.","year":"2013","unstructured":"Zheng J.; Rubin E.J.; Bifani P.; para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis. J Biol Chem 2013,288(32),23447-23456","journal-title":"J Biol Chem"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.bmcl.2019.04.034","volume":"29","author":"Washburn A.","year":"2019","unstructured":"Washburn A.; Abdeen S.; Ovechkina Y.; Dual-targeting Gro-EL\/ES chaperonin and protein tyrosine phosphatase B (PtpB) inhibitors: A polypharmacology strategy for treating Mycobacterium tuberculosis infections. Bioorg Med Chem Lett 2019,29(13),1665-1672","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1039\/C9MD00347A","volume":"10","author":"Kovalenko O.P.","year":"2019","unstructured":"Kovalenko O.P.; Volynets G.P.; Rybak M.Y.; Dual-target inhibitors of mycobacterial aminoacyl-tRNA synthetases among N -benzylidene- N \u2032-thiazol-2-yl-hydrazines. Med Chem Comm 2019,10(12),2161-2169","journal-title":"Med Chem Comm"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s10822-019-00245-5","volume":"33","author":"Volynets G.P.","year":"2019","unstructured":"Volynets G.P.; Starosyla S.A.; Rybak M.Y.; Dual-targeted hit identification using pharmacophore screening. J Comput Aided Mol Des 2019,33(11),955-964","journal-title":"J Comput Aided Mol Des"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2021.1908913","author":"Kumari M.","year":"2021","unstructured":"Kumari M.; Subbarao N.; Identification of novel multitarget antitubercular inhibitors against mycobacterial peptidoglycan biosynthetic mur enzymes by structure-based virtual screening. J Biomol Struct Dyn 2021,1-12","journal-title":"J Biomol Struct Dyn"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"102104","DOI":"10.1016\/j.tube.2021.102104","volume":"129","author":"Kaur P.","year":"2021","unstructured":"Kaur P.; Potluri V.; Ahuja V.K.; A multi-targeting pre-clinical candidate against drug-resistant tuberculosis. Tuberculosis 2021,129,102104","journal-title":"Tuberculosis"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13321-018-0276-9","volume":"10","author":"Passi A.","year":"2018","unstructured":"Passi A.; Rajput N.K.; Wild D.J.; Bhardwaj A.; Rep T.B.; RepTB: A gene ontology based drug repurposing approach for tuberculosis. J Cheminform 2018,10(1),24","journal-title":"J Cheminform"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"e65894","DOI":"10.1371\/journal.pone.0065894","volume":"8","author":"Haupt V.J.","year":"2013","unstructured":"Haupt V.J.; Daminelli S.; Schroeder M.; Drug promiscuity in PDB: Protein binding site similarity is key. PLoS One 2013,8(6),e65894","journal-title":"PLoS One"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"e201401003","DOI":"10.5936\/csbj.201401003","volume":"9","author":"Hu Y.","year":"2014","unstructured":"Hu Y.; Gupta-Ostermann D.; Bajorath J.; Exploring compound promiscuity patterns and multi-target activity spaces. Comput Struct Biotechnol J 2014,9(13),e201401003","journal-title":"Comput Struct Biotechnol J"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"e1000976","DOI":"10.1371\/journal.pcbi.1000976","volume":"6","author":"Kinnings S.L.","year":"2010","unstructured":"Kinnings S.L.; Xie L.; Fung K.H.; Jackson R.M.; Xie L.; Bourne P.E.; The Mycobacterium tuberculosis drugome and its polypharmacological implications. PLOS Comput Biol 2010,6(11),e1000976","journal-title":"PLOS Comput Biol"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"6356","DOI":"10.1038\/srep06356","volume":"4","author":"Anand P.","year":"2014","unstructured":"Anand P.; Chandra N.; Characterizing the pocketome of Mycobacterium tuberculosis and application in rationalizing polypharmacological target selection. Sci Rep 2014,4(1),6356","journal-title":"Sci Rep"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1073\/pnas.0500469102","volume":"102","author":"Weinstein E.A.","year":"2005","unstructured":"Weinstein E.A.; Yano T.; Li L.S.; Inhibitors of type II NADH: Menaquinone oxidoreductase represent a class of antitubercular drugs. Proc Natl Acad Sci 2005,102(12),4548-4553","journal-title":"Proc Natl Acad Sci"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ijid.2014.12.031","volume":"32","author":"Maitra A.","year":"2015","unstructured":"Maitra A.; Bates S.; Kolvekar T.; Devarajan P.V.; Guzman J.D.; Bhakta S.; Repurposing-a ray of hope in tackling extensively drug resistance in tuberculosis. Int J Infect Dis 2015,32,50-55","journal-title":"Int J Infect Dis"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ijantimicag.2016.04.007","volume":"47","author":"Song L.","year":"2016","unstructured":"Song L.; Wu X.; Development of efflux pump inhibitors in antituberculosis therapy. Int J Antimicrob Agents 2016,47(6),421-429","journal-title":"Int J Antimicrob Agents"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"e1000423","DOI":"10.1371\/journal.pcbi.1000423","volume":"5","author":"Kinnings S.L.","year":"2009","unstructured":"Kinnings S.L.; Liu N.; Buchmeier N.; Tonge P.J.; Xie L.; Bourne P.E.; Drug discovery using chemical systems biology: Repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis. PLOS Comput Biol 2009,5(7),e1000423","journal-title":"PLOS Comput Biol"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"7659","DOI":"10.1038\/ncomms8659","volume":"6","author":"Rybniker J.","year":"2015","unstructured":"Rybniker J.; Vocat A.; Sala C.; Lansoprazole is an antituberculous prodrug targeting cytochrome bc1. Nat Commun 2015,6(1),7659","journal-title":"Nat Commun"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.21037\/jtd.2016.10.14","volume":"8","author":"Rendon A.","year":"2016","unstructured":"Rendon A.; Tiberi S.; Scardigli A.; Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives. J Thorac Dis 2016,8(10),2666-2671","journal-title":"J Thorac Dis"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ijid.2016.12.024","volume":"56","author":"Quan D.","year":"2017","unstructured":"Quan D.; Nagalingam G.; Payne R.; Triccas J.A.; New tuberculosis drug leads from naturally occurring compounds. Int J Infect Dis 2017,56,212-220","journal-title":"Int J Infect Dis"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.biotechadv.2015.08.001","volume":"33","author":"Atanasov A.G.","year":"2015","unstructured":"Atanasov A.G.; Waltenberger B.; Pferschy-Wenzig E.M.; Discovery and resupply of pharmacologically active plant-derived natural products: A review. Biotechnol Adv 2015,33(8),1582-1614","journal-title":"Biotechnol Adv"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"113732","DOI":"10.1016\/j.ejmech.2021.113732","volume":"224","author":"Cazzaniga G.","year":"2021","unstructured":"Cazzaniga G.; Mori M.; Chiarelli L.R.; Gelain A.; Meneghetti F.; Villa S.; Natural products against key Mycobacterium tuberculosis enzymatic targets: Emerging opportunities for drug discovery. Eur J Med Chem 2021,224,113732","journal-title":"Eur J Med Chem"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ijmyco.2015.05.004","volume":"4","author":"Nguta J.M.","year":"2015","unstructured":"Nguta J.M.; Appiah-Opong R.; Nyarko A. K.; Yeboah-Manu D.; Addo P; G. Current perspectives in drug discovery against tuberculosis from natural products. Int J Mycobacteriol 2015,4(3),165-183","journal-title":"Int J Mycobacteriol"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1080\/13880209.2017.1309440","volume":"55","author":"Gupta V.K.","year":"2017","unstructured":"Gupta V.K.; Kumar M.M.; Bisht D.; Kaushik A.; Plants in our combating strategies against Mycobacterium tuberculosis: Progress made and obstacles met. Pharm Biol 2017,55(1),1536-1544","journal-title":"Pharm Biol"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1039\/D1NP00011J","volume":"39","author":"Han J.","year":"2022","unstructured":"Han J.; Liu X.; Zhang L.; Quinn R.J.; Feng Y.; Anti-mycobacterial natural products and mechanisms of action. Nat Prod Rep 2022,39(1),77-89","journal-title":"Nat Prod Rep"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"252","DOI":"10.4103\/ijmy.ijmy_109_19","volume":"8","author":"Kumar S.","year":"2019","unstructured":"Kumar S.; Sahu P.; Jena L.; An In silico approach to identify potential inhibitors against multiple drug targets of Mycobacterium tuberculosis. Int J Mycobacteriol 2019,8(3),252-261","journal-title":"Int J Mycobacteriol"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2021.1989040","author":"Kumari M.","year":"2021","unstructured":"Kumari M.; Singh R.; Subbarao N.; Exploring the interaction mechanism between potential inhibitor and multi-target mur enzymes of mycobacterium tuberculosis using molecular docking, molecular dynamics simulation, principal component analysis, free energy landscape, dynamic cross-correlation matrices, vector movements, and binding free energy calculation. J Biomol Struct Dyn 2021,1-30","journal-title":"J Biomol Struct Dyn"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2022.2040593","author":"Kumari M.","year":"2022","unstructured":"Kumari M.; Waseem M.; Subbarao N.; Discovery of multi-target mur enzymes inhibitors with anti-mycobacterial activity through a Scaffold approach. J Biomol Struct Dyn 2022,1-22","journal-title":"J Biomol Struct Dyn"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.2174\/1570180817999200514102750","volume":"17","author":"Ali M.A.","year":"2020","unstructured":"Ali M.A.; Farah M.A.; Lee J.; Al-Anazi K.M.; Al-Hemaid F.M.A.; Molecular insights into the interaction of ursolic acid and cucurbitacin from colocynth with therapeutic targets of Mycobacterium tuberculosis. Lett Drug Des Discov 2020,17(10),1309-1318","journal-title":"Lett Drug Des Discov"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.3390\/antiox10121990","volume":"10","author":"Kumar M.","year":"2021","unstructured":"Kumar M.; Singh S.K.; Singh P.P.; Potential anti-mycobacterium tuberculosis activity of plant secondary metabolites: Insight with molecular docking interactions. Antioxidants 2021,10(12),1990","journal-title":"Antioxidants"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"104694","DOI":"10.1016\/j.compbiomed.2021.104694","volume":"136","author":"Antunes S.S.","year":"2021","unstructured":"Antunes S.S.; Won-Held Rabelo V.; Romeiro N.C.; Natural products from Brazilian biodiversity identified as potential inhibitors of PknA and PknB of M. tuberculosis using molecular modeling tools. Comput Biol Med 2021,136,104694","journal-title":"Comput Biol Med"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/microbiolres12010001","volume":"12","author":"Abdulhamid A.","year":"2021","unstructured":"Abdulhamid A.; Awad T.A.; Ahmed A.E.; Koua F.H.M.; Ismail A.M.; Acetyleugenol from Acacia nilotica (L.) exhibits a strong antibacterial activity and its phenyl and indole analogues show a promising anti-TB potential targeting PknE\/B protein kinases. Microbiol Res 2021,12(1),1-15","journal-title":"Microbiol Res"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"117340","DOI":"10.1016\/j.molliq.2021.117340","volume":"341","author":"Miryala S.K.","year":"2021","unstructured":"Miryala S.K.; Basu S.; Naha A.; Identification of bioactive natural compounds as efficient inhibitors against Mycobacterium tuberculosis protein-targets: A molecular docking and molecular dynamics simulation study. J Mol Liq 2021,341,117340","journal-title":"J Mol Liq"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"12238","DOI":"10.1038\/s41598-018-30209-y","volume":"8","author":"Ali M.T.","year":"2018","unstructured":"Ali M.T.; Blicharska N.; Shilpi J.A.; Seidel V.; Investigation of the anti-TB potential of selected propolis constituents using a molecular docking approach. Sci Rep 2018,8(1),12238","journal-title":"Sci Rep"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/molecules25010038","volume":"25","author":"Wang G.","year":"2019","unstructured":"Wang G.; Dong W.; Lu H.; Enniatin A1, a natural compound with bactericidal activity against mycobacterium tuberculosis in vitro. Molecules 2019,25(1),38","journal-title":"Molecules"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3389\/fgene.2019.00368","volume":"10","author":"Romano J.D.","year":"2019","unstructured":"Romano J.D.; Tatonetti N.P.; Informatics and computational methods in natural product drug discovery: A review and perspectives. Front Genet 2019,10,368","journal-title":"Front Genet"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3390\/molecules25030665","volume":"25","author":"Macalino S.J.Y.","year":"2020","unstructured":"Macalino S.J.Y.; Billones J.B.; Organo V.G.; Carrillo M.C.O.; In silico strategies in tuberculosis drug discovery. Molecules 2020,25(3),665","journal-title":"Molecules"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"Pushpakom S.","year":"2019","unstructured":"Pushpakom S.; Iorio F.; Eyers P.A.; Drug repurposing: Progress, challenges and recommendations. Nat Rev Drug Discov 2019,18(1),41-58","journal-title":"Nat Rev Drug Discov"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"7874","DOI":"10.1021\/jm5006463","volume":"57","author":"Anighoro A.","year":"2014","unstructured":"Anighoro A.; Bajorath J.; Rastelli G.; Polypharmacology: Challenges and opportunities in drug discovery. J Med Chem 2014,57(19),7874-7887","journal-title":"J Med Chem"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1590\/s1806-37562017000000436","volume":"44","author":"Silva D.R.","year":"2018","unstructured":"Silva D.R.; Dalcolmo M.; Tiberi S.; New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis. J Bras Pneumol 2018,44(2),153-160","journal-title":"J Bras Pneumol"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"645485","DOI":"10.3389\/fimmu.2021.645485","volume":"12","author":"Fatima S.","year":"2021","unstructured":"Fatima S.; Bhaskar A.; Dwivedi V.P.; Repurposing immunomodulatory drugs to combat tuberculosis. Front Immunol 2021,12,645485","journal-title":"Front Immunol"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s43141-020-00055-5","volume":"18","author":"Mahmoud D.B.","year":"2020","unstructured":"Mahmoud D.B.; Shitu Z.; Mostafa A.; Drug repurposing of nitazoxanide: Can it be an effective therapy for COVID-19? J Genet Eng Biotechnol 2020,18(1),35","journal-title":"J Genet Eng Biotechnol"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"112175","DOI":"10.1016\/j.ejmech.2020.112175","volume":"192","author":"An Q.","year":"2020","unstructured":"An Q.; Li C.; Chen Y.; Deng Y.; Yang T.; Luo Y.; Repurposed drug candidates for antituberculosis therapy. Eur J Med Chem 2020,192,112175","journal-title":"Eur J Med Chem"},{"key":"ref=174","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.101393","author":"Cardoso N.C.","year":"2021","unstructured":"Cardoso N.C.; Oosthuizen C.B.; Peton N.; Singh V.; Drug repurposing for tuberculosis. Drug Repurposing \u2013 Molecular Aspects and Therapeutic Applications 2021","journal-title":"Drug Repurposing \u2013 Molecular Aspects and Therapeutic Applications"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.3389\/fmicb.2017.02452","volume":"8","author":"Sharma D.","year":"2017","unstructured":"Sharma D.; Dhuriya Y.K.; Deo N.; Bisht D.; Repurposing and revival of the drugs: A new approach to combat the drug resistant tuberculosis. Front Microbiol 2017,8,2452","journal-title":"Front Microbiol"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00044-020-02691-5","volume":"30","author":"Bose P.","year":"2021","unstructured":"Bose P.; Harit A.K.; Das R.; Sau S.; Iyer A.K.; Kashaw S.K.; Tuberculosis: Current scenario, drug targets, and future prospects. Med Chem Res 2021,30(4),807-833","journal-title":"Med Chem Res"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1093\/bmb\/ldw019","volume":"118","author":"Maitra A.","year":"2016","unstructured":"Maitra A.; Bates S.; Shaik M.; Repurposing drugs for treatment of tuberculosis: a role for non-steroidal anti-inflammatory drugs. Br Med Bull 2016,118(1),138-148","journal-title":"Br Med Bull"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3390\/antibiotics10010091","volume":"10","author":"Lee C.","year":"2021","unstructured":"Lee C.; Bhakta S.; The prospect of repurposing immunomodulatory drugs for adjunctive chemotherapy against tuberculosis: A critical review. Antibiotics 2021,10(1),91","journal-title":"Antibiotics"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"101920","DOI":"10.1016\/j.tube.2020.101920","volume":"121","author":"Akinpelu O. I.","year":"2020","unstructured":"Akinpelu O. I.; Lawal M. M.; Kumalo H. M.; Mhlongo N. N.; Drug repurposing: Fusidic acid as a potential inhibitor of M. tuberculosis FtsZ polymerization \u2013 Insight from DFT calculations, molecular docking and molecular dynamics simulations. Tuberculosis 2020,121,101920","journal-title":"Tuberculosis"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"6800","DOI":"10.1038\/s41598-019-43201-x","volume":"9","author":"Pushkaran A.C.","year":"2019","unstructured":"Pushkaran A.C.; Vinod V.; Vanuopadath M.; Combination of repurposed drug diosmin with amoxicillin-clavulanic acid causes synergistic inhibition of mycobacterial growth. Sci Rep 2019,9(1),6800","journal-title":"Sci Rep"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3390\/ijms23020771","volume":"23","author":"Ezquerra-Azn\u00e1rez JM","year":"2022","unstructured":"Ezquerra-Azn\u00e1rez JM; Degiacomi G; Ga\u0161parovi\u010d H; The veterinary anti-parasitic selamectin is a novel inhibitor of the Mycobacterium tuberculosis DprE1 Enzyme. Int J Mol Sci 2022,23(2),771","journal-title":"Int J Mol Sci"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"14688","DOI":"10.33263\/BRIAC116.1468814696","volume":"11","author":"Umapathy D.","year":"2021","unstructured":"Umapathy D.; Soundhararajan R.; Srinivasan H.; Repurposing of FDA-Approved Drugs against Mycobacterium tuberculosis target MMA4 and CmaA2. Biointerface Res Appl Chem 2021,11(6),14688-14696","journal-title":"Biointerface Res Appl Chem"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1007\/s11030-021-10296-2","volume":"26","author":"Madugula S.S.","year":"2022","unstructured":"Madugula S.S.; Nagamani S.; Jamir E.; Priyadarsinee L.; Sastry G.N.; Drug repositioning for anti-tuberculosis drugs: An in silico polypharmacology approach. Mol Divers 2022,26(3),1675-1695","journal-title":"Mol Divers"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.3390\/molecules24234373","volume":"24","author":"Battah B.","year":"2019","unstructured":"Battah B.; Chemi G.; Butini S.; A repurposing approach for uncovering the anti-tubercular activity of fda-approved drugs with potential multi-targeting profiles. Molecules 2019,24(23),4373","journal-title":"Molecules"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1080\/07391102.2019.1637280","volume":"38","author":"Rani J.","year":"2020","unstructured":"Rani J.; Silla Y.; Borah K.; Ramachandran S.; Bajpai U.; Repurposing of FDA-approved drugs to target MurB and MurE enzymes in Mycobacterium tuberculosis. J Biomol Struct Dyn 2020,38(9),2521-2532","journal-title":"J Biomol Struct Dyn"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"113568","DOI":"10.1016\/j.ejmech.2021.113568","volume":"222","author":"Shinde Y.","year":"2021","unstructured":"Shinde Y.; Ahmad I.; Surana S.; Patel H.; The Mur Enzymes Chink in the Armour of Mycobacterium tuberculosis cell wall. Eur J Med Chem 2021,222,113568","journal-title":"Eur J Med Chem"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.mehy.2017.04.005","volume":"103","author":"Brindha S.","year":"2017","unstructured":"Brindha S.; Vincent S.; Velmurugan D.; Ananthakrishnan D.; Sundaramurthi J.C.; Gnanadoss J.J.; Bioinformatics approach to prioritize known drugs towards repurposing for tuberculosis. Med Hypotheses 2017,103,39-45","journal-title":"Med Hypotheses"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"W350-6","DOI":"10.1093\/nar\/gkz391","volume":"47","author":"Ab Ghani N.S.","year":"2019","unstructured":"Ab Ghani N.S.; Ramlan E.I.; Firdaus-Raih M.; Drug ReposER: A web server for predicting similar amino acid arrangements to known drug binding interfaces for potential drug repositioning. Nucleic Acids Res 2019,47(W1),W350-6","journal-title":"Nucleic Acids Res"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3390\/antibiotics10081005","volume":"10","author":"Kleandrova V.V.","year":"2021","unstructured":"Kleandrova V.V.; Scotti M.T.; Speck-Planche A.; Computational drug repurposing for antituberculosis therapy: Discovery of multistrain inhibitors. Antibiotics 2021,10(8),1005","journal-title":"Antibiotics"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1016\/S1473-3099(18)30110-5","volume":"18","author":"Tiberi S.","year":"2018","unstructured":"Tiberi S.; du Plessis N.; Walzl G.; Tuberculosis: Progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis 2018,18(7),e183-e198","journal-title":"Lancet Infect Dis"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41385-019-0226-5","volume":"13","author":"Young C.","year":"2020","unstructured":"Young C.; Walzl G.; Du Plessis N.; Therapeutic host-directed strategies to improve outcome in tuberculosis. Mucosal Immunol 2020,13(2),190-204","journal-title":"Mucosal Immunol"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00281-015-0537-x","volume":"38","author":"Kiran D.","year":"2016","unstructured":"Kiran D.; Podell B.K.; Chambers M.; Basaraba R.J.; Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: A review. Semin Immunopathol 2016,38(2),167-183","journal-title":"Semin Immunopathol"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1080\/21505594.2018.1536598","volume":"10","author":"Paik S.","year":"2019","unstructured":"Paik S.; Kim J.K.; Chung C.; Jo E.K.; Autophagy: A new strategy for host-directed therapy of tuberculosis. Virulence 2019,10(1),448-459","journal-title":"Virulence"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"660916","DOI":"10.3389\/fimmu.2021.660916","volume":"12","author":"Krug S.","year":"2021","unstructured":"Krug S.; Parveen S.; Bishai W.R.; Host-directed therapies: Modulating inflammation to treat tuberculosis. Front Immunol 2021,12,660916","journal-title":"Front Immunol"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/nchembio.1917","volume":"11","author":"Guler R.","year":"2015","unstructured":"Guler R.; Brombacher F.; Host-directed drug therapy for tuberculosis. Nat Chem Biol 2015,11(10),748-751","journal-title":"Nat Chem Biol"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"112931","DOI":"10.1016\/j.ejmech.2020.112931","volume":"209","author":"Wetzel C.","year":"2021","unstructured":"Wetzel C.; Lonneman M.; Wu C.; Polypharmacological drug actions of recently FDA approved antibiotics. Eur J Med Chem 2021,209,112931","journal-title":"Eur J Med Chem"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1038\/s41467-021-23659-y","volume":"12","author":"Wang H.","year":"2021","unstructured":"Wang H.; Wang M.; Xu X.; Multi-target mode of action of silver against Staphylococcus aureus endows it with capability to combat antibiotic resistance. Nat Commun 2021,12(1),3331","journal-title":"Nat Commun"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"111660","DOI":"10.1016\/j.ejmech.2019.111660","volume":"183","author":"Braga S.S.","year":"2019","unstructured":"Braga S.S.; Multi-target drugs active against leishmaniasis: A paradigm of drug repurposing. Eur J Med Chem 2019,183,111660","journal-title":"Eur J Med Chem"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1021\/acsinfecdis.2c00537","volume":"9","author":"Stampolaki M.","year":"2023","unstructured":"Stampolaki M.; Malwal S.R.; Alvarez-Cabrera N.; Synthesis and testing of analogs of the tuberculosis drug candidate sq109 against bacteria and protozoa: Identification of lead compounds against Mycobacterium abscessus and Malaria Parasites. ACS Infect Dis 2023,9(2),342-364","journal-title":"ACS Infect Dis"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.addr.2016.04.026","volume":"102","author":"Hoagland D.T.","year":"2016","unstructured":"Hoagland D.T.; Liu J.; Lee R.B.; Lee R.E.; New agents for the treatment of drug-resistant Mycobacterium tuberculosis. Adv Drug Deliv Rev 2016,102,55-72","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/med.21602","volume":"40","author":"Bahuguna A.","year":"2020","unstructured":"Bahuguna A.; Rawat D.S.; An overview of new antitubercular drugs, drug candidates, and their targets. Med Res Rev 2020,40(1),263-292","journal-title":"Med Res Rev"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","volume":"382","author":"Conradie F.","year":"2020","unstructured":"Conradie F.; Diacon A.H.; Ngubane N.; Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med 2020,382(10),893-902","journal-title":"N Engl J Med"},{"key":"ref=203","unstructured":"FDA approves new treatment for highly drug-resistant forms of \ttuberculosis | TB Alliance. Available from:"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450124666230505145335","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/216602\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450124666230505145335","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T11:33:29Z","timestamp":1695123209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/216602\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":203,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,8,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450124666230505145335","relation":{},"ISSN":["1389-4501"],"issn-type":[{"type":"print","value":"1389-4501"}],"subject":[],"published":{"date-parts":[[2023,8,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-09-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}